AAAAAA

   
Results: 1-11 |
Results: 11
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
Authors: Burstein, HJ Kuter, I Campos, SM Gelman, RS Tribou, L Parker, LM Manola, J Younger, J Matulonis, U Bunnell, CA Partridge, AH Richardson, PG Clarke, K Shulman, LN Winer, EP
Citation: Hj. Burstein et al., Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer, J CL ONCOL, 19(10), 2001, pp. 2722-2730
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patientswith refractory solid malignancies
Authors: Bunnell, CA Supko, JG Eder, JP Clark, JW Lynch, TJ Kufe, DW Shulman, LN
Citation: Ca. Bunnell et al., Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patientswith refractory solid malignancies, CANC CHEMOT, 48(5), 2001, pp. 347-355
Standardization of carcinoembryonic antigen testing in the setting of clinical laboratory consolidation
Authors: Delgado, JC Shulman, LN Gudrais, PG Fischer, GA Ferguson, DO Winkelman, JW Tanasijevic, MJ
Citation: Jc. Delgado et al., Standardization of carcinoembryonic antigen testing in the setting of clinical laboratory consolidation, LAB MED, 32(2), 2001, pp. 92-95
Phase II study of the multitargeted antifolate LY231514 (ALIMTA (TM), MTA,pemetrexed disodium) in patients with advanced pancreatic cancer
Authors: Miller, KD Picus, J Blanke, C John, W Clark, J Shulman, LN Thornton, D Rowinsky, E Loehrer, PJ
Citation: Kd. Miller et al., Phase II study of the multitargeted antifolate LY231514 (ALIMTA (TM), MTA,pemetrexed disodium) in patients with advanced pancreatic cancer, ANN ONCOL, 11(1), 2000, pp. 101-103
Docetaxel administered on a weekly basis for metastatic breast cancer
Authors: Burstein, HJ Manola, J Younger, J Parker, LM Bunnell, CA Scheib, R Matulonis, UA Garber, JE Clarke, KD Shulman, LN Winer, EP
Citation: Hj. Burstein et al., Docetaxel administered on a weekly basis for metastatic breast cancer, J CL ONCOL, 18(6), 2000, pp. 1212-1219
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine - A pharmacologically based regimen
Authors: Sternberg, DW Aird, W Neuberg, D Thompson, L MacNeill, K Amrein, P Shulman, LN
Citation: Dw. Sternberg et al., Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine - A pharmacologically based regimen, CANCER, 88(9), 2000, pp. 2037-2041
Concurrent CMF and radiation therapy for early stage breast cancer: Results of a pilot study
Authors: Dubey, A Recht, A Come, SE Gelman, RS Silver, B Harris, JR Shulman, LN
Citation: A. Dubey et al., Concurrent CMF and radiation therapy for early stage breast cancer: Results of a pilot study, INT J RAD O, 45(4), 1999, pp. 877-884
Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer
Authors: Hardenbergh, PH Recht, A Gollamudi, S Come, SE Hayes, DF Shulman, LN O'Neill, A Gelman, RS Silver, B Harris, JR
Citation: Ph. Hardenbergh et al., Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer, INT J RAD O, 45(1), 1999, pp. 69-72
Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
Authors: Shulman, LN Buswell, L Riese, N Doherty, N Loeffler, JS von Roemeling, RW Coleman, CN
Citation: Ln. Shulman et al., Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors, INT J RAD O, 44(2), 1999, pp. 349-353
Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission
Authors: Shulman, LN Tarbell, NJ Storen, E Marcus, K Mauch, PM
Citation: Ln. Shulman et al., Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission, INT J RAD O, 42(5), 1998, pp. 1113-1117
Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma
Authors: Abner, AL Collins, L Peiro, G Recht, A Come, S Shulman, LN Silver, B Nixon, A Harris, JR Schnitt, SJ Connolly, JL
Citation: Al. Abner et al., Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma, CANCER, 83(12), 1998, pp. 2502-2508
Risultati: 1-11 |